Suchergebnisse - "Sension, Michael G"

PubPharm (18)

1

Cabotegravir + Rilpivirine Long-Acting Injections for HIV Treatment in the US : Real World Data from the OPERA Cohort

enthalten in: Infectious diseases and therapy | 2023

von Sension, M. | Brunet, L. | Hsu, R. | +9

2

Cabotegravir + Rilpivirine Long-Acting Injections for HIV Treatment in the US: Real World Data from the OPERA Cohort

enthalten in: Infectious diseases and therapy | 2023

von Sension, M. | Brunet, L. | Hsu, R. | +9

3

Efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients : analysis of the etravirine early access program in the United States

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2010

von Towner, W. | Lalezari, J. | Sension, M. | +10

4

Pregnancy, Contraceptive Use, and HIV Acquisition in HPTN 039: Relevance for HIV Prevention Trials Among African Women

enthalten in: Journal of acquired immune deficiency syndromes | 2010

von Towner, W. | Lalezari, J. | Sension, M. | +10

5

Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine : 96-week results from COL100758

enthalten in: AIDS research and human retroviruses | 2009

von Hicks, C. | DeJesus, E. | Sloan, L. | +8

6

Comparison of Once-Daily Fosamprenavir Boosted with Either 100 or 200 mg of Ritonavir, in Combination with Abacavir-Lamivudine: 96-Week Results from COL100758

enthalten in: Aids research and human retroviruses | 2009

von Hicks, C. | Dejesus, E. | Sloan, L. | +7

7

Long-Term suppression of HIV infection : benefits and limitations of current treatment options

enthalten in: The Journal of the Association of Nurses in AIDS Care : JANAC | 2007

von Sension, M.

8

Long-Term Suppression of HIV Infection: Benefits and Limitations of Current Treatment Options

enthalten in: Journal of the Association of Nurses in AIDS Care | 2007

von Sension, M.

9

Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment

enthalten in: BMC infectious diseases | 2005

von Keiser, P. | Sension, M. | DeJesus, E. | +10

10

Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment

enthalten in: BMC infectious diseases | 2005

von Keiser, P. | Sension, M. | DeJesus, E. | +9